ACTA1 and kidney injury: Researchers [70,71,72] injected microvesicles derived from Wharton’s Jelly-derived MSCs (WJ-MSCs) into rats with kidney injuries, and there were clear improvements in renal function, decreased α-SMA and TGF-β1 expression and improved survival rates.